论文部分内容阅读
目的探讨环孢菌素A(CsA)对多发性骨髓瘤(MM)患者可溶性耐药相关钙结合蛋白(Sorcin)基因表达和临床疗效的影响。方法选择32例MM患者(MM组)和27例正常人(对照组)为研究对象。MM组均行联合化疗,其中临床耐药者(M亚组)在联合化疗前24 h开始予CsA 8~12 mg/(kg.d)静滴或口服,3 d后改半量用2 d。治疗前后采用RT-PCR方法检测两组骨髓Sorcin基因表达率,观察临床疗效。结果治疗前Sorcin基因表达率MM组和对照组分别为31.25%和0.30%(P<0.05),M亚组和非临床耐药者(UM亚组)分别为75.00%和16.67%(P<0.05);M亚组治疗前后Sorcin基因表达率分别为75.00%和62.50%(P>0.05),完全缓解(CR)率和总有效率分别为25.00%和62.50%(P<0.05)。结论CsA可逆转MM患者多药耐药,增强临床疗效,但其机制与Sorcin基因表达无关。
Objective To investigate the effect of cyclosporin A (CsA) on the expression of soluble resistance-associated protein (Sorcin) and clinical efficacy in patients with multiple myeloma (MM). Methods Thirty-two MM patients (MM group) and 27 normal controls (control group) were selected as the study subjects. The patients in MM group were treated with combination chemotherapy, and those in clinical drug-resistant group (M subgroup) received CsA 8-12 mg / (kg.d) intravenously or orally 24 hours before the combination chemotherapy. Before and after treatment, the expression of Sorcin gene in bone marrow of both groups was detected by RT-PCR, and the clinical effect was observed. Results The expression of Sorcin before treatment was 31.25% in the MM group and 0.30% in the control group (P <0.05), while the M subgroup and the non-clinical drug resistance group were 75.00% and 16.67% (P <0.05) ). The rates of complete remission (CR) and total effective rate of the M group before and after treatment were 75.00% and 62.50% (P> 0.05). The rates of complete remission (CR) and total effective rate were 25.00% and 62.50%, respectively. Conclusion CsA can reverse the multidrug resistance in MM patients and enhance the clinical curative effect, but the mechanism is not related to the expression of Sorcin gene.